ECSP056090A - Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar - Google Patents

Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar

Info

Publication number
ECSP056090A
ECSP056090A EC2005006090A ECSP056090A ECSP056090A EC SP056090 A ECSP056090 A EC SP056090A EC 2005006090 A EC2005006090 A EC 2005006090A EC SP056090 A ECSP056090 A EC SP056090A EC SP056090 A ECSP056090 A EC SP056090A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
sugar
solid pharmaceutical
spirit
composition including
Prior art date
Application number
EC2005006090A
Other languages
English (en)
Spanish (es)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of ECSP056090A publication Critical patent/ECSP056090A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EC2005006090A 2003-04-08 2005-10-07 Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar ECSP056090A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
ECSP056090A true ECSP056090A (es) 2006-03-01

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006090A ECSP056090A (es) 2003-04-08 2005-10-07 Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar

Country Status (41)

Country Link
US (11) US20060275357A1 (instruction)
EP (5) EP1613288B1 (instruction)
JP (3) JP5495467B2 (instruction)
KR (3) KR20050121712A (instruction)
CN (2) CN1767819B (instruction)
AR (3) AR043987A1 (instruction)
AT (3) AT501681B1 (instruction)
AU (1) AU2004228929B2 (instruction)
BE (2) BE1015972A5 (instruction)
BR (1) BRPI0409250B8 (instruction)
CA (2) CA2707750A1 (instruction)
CL (2) CL2004000745A1 (instruction)
CY (3) CY1110260T1 (instruction)
DE (4) DE102004016947A1 (instruction)
DK (2) DK2316431T3 (instruction)
EC (1) ECSP056090A (instruction)
ES (3) ES2320767T3 (instruction)
FR (2) FR2854073B1 (instruction)
GB (1) GB2400318B (instruction)
GR (1) GR1005052B (instruction)
HR (3) HRP20100601B1 (instruction)
HU (2) HUE028247T2 (instruction)
IL (3) IL170888A (instruction)
IS (2) IS2682B (instruction)
IT (1) ITMI20040682A1 (instruction)
LU (1) LU91867I2 (instruction)
MA (1) MA27729A1 (instruction)
MX (1) MXPA05010860A (instruction)
MY (1) MY141249A (instruction)
NO (4) NO329332B1 (instruction)
NZ (3) NZ542622A (instruction)
PE (5) PE20050396A1 (instruction)
PL (2) PL1613288T3 (instruction)
PT (1) PT1613288E (instruction)
RU (5) RU2358716C2 (instruction)
SG (1) SG175449A1 (instruction)
SI (2) SI2316431T1 (instruction)
TN (1) TNSN05256A1 (instruction)
TW (1) TWI332847B (instruction)
WO (1) WO2004089341A1 (instruction)
ZA (1) ZA200507394B (instruction)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
JO2655B1 (en) * 2005-09-09 2012-06-17 نوفارتيس ايه جي Treatment of autoimmune diseases
MY145757A (en) 2005-11-09 2012-04-13 Proteolix Inc Compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
CN102579387A (zh) * 2006-09-26 2012-07-18 诺瓦提斯公司 包含s1p调节剂的药物组合物
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
SI2140867T2 (sl) 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Farmacevtski sestavek
CL2008002966A1 (es) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
PT2952177T (pt) * 2007-10-12 2021-04-26 Novartis Ag Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p)
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
RU2562571C2 (ru) 2008-06-20 2015-09-10 Новартис Аг Педиатрические композиции для лечения рассеянного склероза
US11166917B2 (en) * 2008-06-20 2021-11-09 Merck Patent Gmbh Direct injection moldable and rapidly disintegrating tablet matrix
HRP20120121T1 (hr) * 2008-09-04 2012-03-31 Cargill Incorporated Tabletiranje eritritola
CN102256616A (zh) 2008-10-21 2011-11-23 欧尼斯治疗公司 与肽环氧酮的联合疗法
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
KR101393994B1 (ko) * 2008-11-11 2014-05-14 노파르티스 아게 핑골리모드 ｈｃｌ의 결정질 형태
RU2464271C1 (ru) 2008-12-17 2012-10-20 Дайити Санкио Компани, Лимитед Способ получения производного диамина
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN103330690A (zh) * 2009-06-18 2013-10-02 第一三共株式会社 溶解性改善的药用组合物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
WO2012002538A1 (ja) 2010-07-02 2012-01-05 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
MA34897B1 (fr) 2011-01-07 2014-02-01 Novartis Ag Formulations d'immunosupresseurs
EP2665471B1 (en) 2011-01-19 2017-12-27 Pathologica, LLC. Controlled release oral pharmaceutical dosage forms comprising mgbg
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (en) * 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
EP2742941B1 (en) 2011-08-10 2018-04-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CA2896977C (en) 2013-01-08 2021-12-07 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016118515A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
CA3208122A1 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
CA2126337C (en) 1992-10-21 2003-06-24 Tetsuro Fujita 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
RU2156127C2 (ru) 1995-12-28 2000-09-20 Еситоми Фармасьютикал Индустриз, Лтд. Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
SI0990440T1 (sl) * 1997-02-27 2009-04-30 Novartis Ag Farmacevtski sestavek, ki obsega 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol, lecitin in saharid
IL132208A (en) 1997-04-04 2003-07-31 Mitsubishi Pharma Corp 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
CZ20032560A3 (cs) 2001-03-26 2003-12-17 Novartis Ag Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
BRPI0212894B8 (pt) 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen

Also Published As

Publication number Publication date
PL1613288T3 (pl) 2009-07-31
DE102004016947A1 (de) 2004-10-21
TWI332847B (en) 2010-11-11
NZ542622A (en) 2009-01-31
BRPI0409250A (pt) 2006-03-28
DE602004017847D1 (de) 2009-01-02
FR2854073A1 (fr) 2004-10-29
DE202004021680U1 (de) 2010-04-22
HRP20100601A2 (hr) 2011-03-31
FR11C0036I1 (fr) 2011-10-14
RU2005134173A (ru) 2006-09-10
AR043987A1 (es) 2005-08-17
HRP20100600A2 (hr) 2011-03-31
ZA200507394B (en) 2007-03-28
NZ586280A (en) 2011-12-22
US20060275357A1 (en) 2006-12-07
GB2400318A (en) 2004-10-13
DK1613288T3 (da) 2009-03-23
BRPI0409250B8 (pt) 2022-01-18
NO20100250L (no) 2006-01-09
MY141249A (en) 2010-03-31
US20200237690A1 (en) 2020-07-30
SI2316431T1 (sl) 2016-04-29
TW200503784A (en) 2005-02-01
RU2009105403A (ru) 2010-08-27
EP2769713A1 (en) 2014-08-27
EP2319502A1 (en) 2011-05-11
BE2011C030I2 (instruction) 2023-03-07
NO2011016I1 (no) 2011-09-19
HUS1100016I1 (hu) 2016-08-29
IL197578A (en) 2015-10-29
AU2004228929A1 (en) 2004-10-21
IL170888A (en) 2010-06-16
PE20150676A1 (es) 2015-05-17
AU2004228929B2 (en) 2008-02-07
NO335120B1 (no) 2014-09-22
EP2316431B1 (en) 2015-09-30
IS2682B (is) 2010-10-15
NO2011016I2 (no) 2012-08-27
RU2010146697A (ru) 2012-05-27
AT501681B1 (de) 2012-04-15
CA2521325C (en) 2010-09-14
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
HK1091114A1 (en) 2007-01-12
CY1117071T1 (el) 2017-04-05
CY1110260T1 (el) 2014-04-09
US20170290787A1 (en) 2017-10-12
HUE028247T2 (en) 2016-12-28
CN1767819A (zh) 2006-05-03
RU2475237C2 (ru) 2013-02-20
HRP20050886B1 (en) 2011-01-31
US20090203798A1 (en) 2009-08-13
EP2008650A2 (en) 2008-12-31
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
KR20050121712A (ko) 2005-12-27
AR078782A2 (es) 2011-11-30
HK1155647A1 (en) 2012-05-25
EP1613288B1 (en) 2008-11-19
TNSN05256A1 (en) 2007-07-10
GB2400318B (en) 2005-08-10
JP5543298B2 (ja) 2014-07-09
ATE414508T1 (de) 2008-12-15
RU2012148593A (ru) 2014-05-20
RU2358716C2 (ru) 2009-06-20
JP2004307506A (ja) 2004-11-04
NO334116B1 (no) 2013-12-16
GB0407819D0 (en) 2004-05-12
AT501681A1 (de) 2006-10-15
CY2011013I2 (el) 2014-04-09
CY2011013I1 (el) 2014-04-09
FR11C0036I2 (fr) 2023-12-29
ES2228282B1 (es) 2006-02-16
LU91867I2 (fr) 2011-11-08
GR20040100121A (el) 2004-12-17
KR20110005320A (ko) 2011-01-17
ITMI20040682A1 (it) 2004-07-06
US20130108675A1 (en) 2013-05-02
MXPA05010860A (es) 2006-05-25
NO329332B1 (no) 2010-09-27
US20190175527A1 (en) 2019-06-13
KR101367574B1 (ko) 2014-02-25
PT1613288E (pt) 2009-02-25
SI1613288T1 (sl) 2009-04-30
DK2316431T3 (en) 2016-01-11
PE20090743A1 (es) 2009-07-17
PE20050396A1 (es) 2005-07-05
GR1005052B (el) 2005-11-30
PE20130200A1 (es) 2013-03-09
MA27729A1 (fr) 2006-01-02
WO2004089341A1 (en) 2004-10-21
IL242037A0 (en) 2015-11-30
US8324283B2 (en) 2012-12-04
ES2556947T3 (es) 2016-01-21
EP1613288A1 (en) 2006-01-11
US20220031609A1 (en) 2022-02-03
IS8114A (is) 2005-11-01
JP2011006461A (ja) 2011-01-13
CL2004000745A1 (es) 2005-02-11
HRP20100601B1 (hr) 2016-12-02
US20110105620A1 (en) 2011-05-05
KR20120101148A (ko) 2012-09-12
SG175449A1 (en) 2011-11-28
IL197578A0 (en) 2011-07-31
ES2320767T3 (es) 2009-05-28
RU2475236C2 (ru) 2013-02-20
EP2008650A3 (en) 2011-04-27
BRPI0409250B1 (pt) 2017-07-11
CA2707750A1 (en) 2004-10-21
AR078781A2 (es) 2011-11-30
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
RU2010147000A (ru) 2012-08-10
IS8885A (is) 2010-02-25
HRP20050886A2 (en) 2006-11-30
LU91867I9 (instruction) 2019-01-03
US20080311188A1 (en) 2008-12-18
CN101797241A (zh) 2010-08-11
NZ592339A (en) 2012-09-28
US20140011885A1 (en) 2014-01-09
JP2013177404A (ja) 2013-09-09
IE20040246A1 (en) 2004-12-15
CA2521325A1 (en) 2004-10-21
ES2228282A1 (es) 2005-04-01
US20140255497A1 (en) 2014-09-11
NO20055231D0 (no) 2005-11-07
JP5495467B2 (ja) 2014-05-21
NO20131287L (no) 2006-01-09
FR2854073B1 (fr) 2008-03-14
PE20131352A1 (es) 2013-11-14
AT504853A2 (de) 2008-08-15
CN1767819B (zh) 2010-07-28
DE122011100047I1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
ECSP056090A (es) Composición farmacéutica sólida que comprende un agonista del receptor de s1p, y un alcohol de azúcar
MX2009010289A (es) Composiciones para administracion nasal.
ECSP055569A (es) Forma de dosificación de pramipexol en una dosis única diaria
PA8639701A1 (es) Composicion del anticuerpo her2
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR059357A1 (es) Formulaciones farmaceuticas
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
NO20060510L (no) Emulgerende systemer inneholdende azetidinderivater
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
NO20064808L (no) Orale matrixformuleringer med licarbazepin
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
UY30065A1 (es) Composiciones farmacéuticas para la erradicación de helicobacter pylori
NO20062668L (no) Orale formuleringer av desoxypeganin og anvendelser derav
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
HN2002000355A (es) Combinacion farmaceutica
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon
MY142039A (en) New association between a heterocyclic compound and an antioxidant agent, and pharmaceutical compositions containing them
ECSP055749A (es) Formulacion de tramadol de liberacion sostenida con eficacia de 24 horas
CL2008001541A1 (es) Composicion farmaceutica solida para administracion oral que comprende un agonista del receptor de fosfato de esfingosina-1 (s1p) y un alcohol de azucar (div. sol. 745-04).
ECSP045461A (es) Unidades de dosificación progestagénica
CL2008003633A1 (es) Uso de una matriz fisica que comprende un eter de celulosa para la manufactura de una formulacion que proporciona una liberacion controlada de una sal de oxicodona, util en el tratamiento del dolor.